Revenue stood at KD 99 million, representing a growth of 6.5% compared to 2023 full-year revenue. The Non-Food Business Line accounted for 34.6% of Group Revenue. The Business Line comprises the ...

Kering lost around $3 billion in stockmarket value on Friday after the group chose in-house talent Demna to reinvigorate its ...

The agreement was signed concurrently with Nxera’s assignment of its option to these same rights from Idorsia Pharmaceuticals Ltd under its agreement in July 2023 to acquire Idorsia Pharmaceuticals ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

BRIDGEWATER, N.J., February 20, 2025--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

Both are highly experienced in their respective specialties and will provide invaluable advice and guidance to the Group as we further ... External Director. Nxera Pharma is a technology powered ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated ...

In 2024, the company sold two of these activities, representing about €300 million in annual sales, the yeast extract business to Lesaffre and the marine lipids activities to KD Pharma Group.

The bank recorded a notable increase in net profits, reaching JOD 194.3 million (KD 84.4 million), reflecting a rise of 115.8 % compared to the previous year. These strong results highlight the ...

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group.